MBQIF (MindBio Therapeutics) Debt-to-Equity: -1.77 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

MBQIF MindBio Therapeutics Corp MBQIF
10 GF Score
Price $0.15
! 1 Warning Sign
View Full Analysis

What is MindBio Therapeutics Debt-to-Equity?

MindBio Therapeutics MBQIF -11.26% 10 Debt-to-Equity is -1.77 as of Mar. 2026. GuruFocus rates MBQIF with a GF Score™ of 10/100. The stock has 1 warning sign investors should review. Among 956 Biotechnology companies, MindBio Therapeutics ranks worse than 104602.41% on this metric.

MindBio Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $2.24 Mil. MindBio Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2026 was $0.00 Mil. MindBio Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $-1.27 Mil. MindBio Therapeutics's debt to equity for the quarter that ended in Mar. 2026 was -1.77.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MindBio Therapeutics's Debt-to-Equity or its related term are showing as below:

MBQIF' s Debt-to-Equity Range Over the Past 10 Years
Min: -1.77   Med: -0.93   Max: -0.83
Current: -1.77

During the past 5 years, the highest Debt-to-Equity Ratio of MindBio Therapeutics was -0.83. The lowest was -1.77. And the median was -0.93.

MBQIF's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.16 vs MBQIF: -1.77

MindBio Therapeutics  (OTCPK:MBQIF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MindBio Therapeutics Debt-to-Equity Related Terms

MindBio Therapeutics Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for MindBio Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MindBio Therapeutics Debt-to-Equity Chart

MindBio Therapeutics Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Debt-to-Equity
-1.01 -1.06 -0.93 -0.93 -0.94

MindBio Therapeutics Quarterly Data
Jun21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.83 -0.94 -0.93 -1.14 -1.77

MBQIF vs : Debt-to-Equity Comparison

For the Biotechnology subindustry, MindBio Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MindBio Therapeutics Debt-to-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MindBio Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MindBio Therapeutics's Debt-to-Equity falls into.


MBQIF
10GF Score
MindBio Therapeutics Corp MBQIF
Debt-to-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

MindBio Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MindBio Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Jun. 2025 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.24 + 0) / -2.382
=-0.94

MindBio Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2026 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(2.24 + 0) / -1.265
=-1.77

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of -1.77 mean?
MindBio Therapeutics (MBQIF) has a Debt-to-Equity of -1.77 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MindBio Therapeutics and its competitors. According to the industry distribution chart, MindBio Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry.
Is MindBio Therapeutics' Debt-to-Equity too high?
MindBio Therapeutics' current Debt-to-Equity is -1.77. Based on the distribution chart, MindBio Therapeutics ranks #999999 out of 956 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, MindBio Therapeutics has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does MindBio Therapeutics' Debt-to-Equity compare to ?
According to the Biotechnology industry distribution chart, MindBio Therapeutics ranks #999999 out of 956 companies for Debt-to-Equity. This places MindBio Therapeutics in the lower half of its industry. The industry median Debt-to-Equity is 0.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Biotechnology company?
The median Debt-to-Equity among Biotechnology companies is 0.16, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MindBio Therapeutics and its competitors. For the Biotechnology industry, the median Debt-to-Equity is 0.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MindBio Therapeutics's current Debt-to-Equity is -1.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MindBio Therapeutics stock overvalued right now?
MindBio Therapeutics (MBQIF) has a current Debt-to-Equity of -1.77. The current Debt-to-Equity is -1.77. MindBio Therapeutics' overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MindBio Therapeutics (MBQIF), the current Debt-to-Equity is -1.77 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MindBio Therapeutics Business Description

Comparable Companies
Other Exchanges WF60:GermanyMBIO:Canada
Address 91-97 William Steet, Level 4, Melbourne, VIC, AUS, 3000
MindBio Therapeutics Corp is engaged in the research, development, and testing of psychedelic substances as a potential treatment for the management of a broad range of mental health conditions. The company invests in clinical research to discover potential new treatment options and aims to create novel medicines and treatment regimes from breakthrough microdosing studies. Geographically, the company's activities take place in Australia.
10GF Score

Get the complete analysis for MBQIF

Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.15
Price